For Arcturus Therapeutics Holdings Inc. (ARCT), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.2. Splitting up the data highlights that, out of 13 analysts covering the stock, 1 rated the stock as a Sell while none recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 8 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.89 in the current quarter.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) trade information
Upright in the green during last session for gaining 3.85%, in the last five days ARCT remained trading in the green while hitting it’s week-highest on Friday, Jan 08 when the stock touched $81.35- price level, adding 19.72% to its value on the day. Arcturus Therapeutics Holdings Inc.’s shares saw a change of 50.55% in year-to-date performance and have moved 32.29% in past 5-day. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) showed a performance of -38.39% in past 30-days. Number of shares sold short was 3.17 Million shares which calculate 1.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $101.67 to the stock, which implies a rise of 55.67% to its current value. Analysts have been projecting $46 as a low price target for the stock while placing it at a high target of $152. It follows that stock’s current price would jump +132.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -29.57% for stock’s current value.
Arcturus Therapeutics Holdings Inc. (ARCT) estimates and forecasts
Statistics highlight that Arcturus Therapeutics Holdings Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +20.94% of value to its shares in past 6 months, showing an annual growth rate of -46.05% while that of industry is 14.5. Apart from that, the company came lowering its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to decline by -17.1% in the current quarter and calculating -4.5% decline in the next quarter. This year revenue growth is estimated to drop -53.1% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.36 Million for the same. And 7 analysts are in estimates of company making revenue of $8.56 Million in the next quarter that will end on March 01, 2021. Company posted $2.97 Million and $2.65 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -20.5% while estimating it to be 223.5% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 33.7% during past 5 years. In 2021, company’s earnings growth rate is likely to be around 0.5% while estimates for its earnings growth in next 5 years are of 0%
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s Major holders
Insiders are in possession of 18.43% of company’s total shares while institution are holding 70.46% percent of that, with stock having share float percentage of 86.38%. Investors also watch the number of corporate investors in a company very closely, which is 183 institutions for Arcturus Therapeutics Holdings Inc. that are currently holding shares of the company. ARK Investment Management, LLC is the top institutional holder at ARCT for having 2.5 Million shares of worth $107.07 Million. And as of September 29, 2020, it was holding 10.19% of the company’s outstanding shares.
The second largest institutional holder is Healthcor Management LP, which was holding about 1.59 Million shares on September 29, 2020. The number of shares represents firm’s hold over 6.51% of outstanding shares, having a total worth of $68.4 Million.
On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF and Federated Hermes Kaufmann Small Cap Fund are the top two Mutual Funds which own company’s shares. As of December 30, 2020, the former fund manager was holding 3935339 shares of worth $170.72 Million or 16.07% of the total outstanding shares. The later fund manager was in possession of 799Thousand shares on October 30, 2020, making its stake of worth around $43.21 Million in the company or a holder of 3.26% of company’s stock.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.